Review





Similar Products

egfr activating mutations  (Vitro Biopharma Inc)
86
Vitro Biopharma Inc egfr activating mutations
Egfr Activating Mutations, supplied by Vitro Biopharma Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr-activating+mutations/activating+egfr+mutations/fda_document____drugsatfda_docs_slash_nda_slash_2013_slash_201292orig1s000medr-107-26-8
Average 86 stars, based on 1 article reviews
egfr activating mutations - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
egfr-activating mutations  (MedGenome)
90
MedGenome egfr-activating mutations
Egfr Activating Mutations, supplied by MedGenome, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr-activating+mutations/egfr+activating+mutations/pm40414381-144-18-6
Average 90 stars, based on 1 article reviews
egfr-activating mutations - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
adenocarcinomas specimens from patients’ surgically resected tumors (srt) with egfr activating mutations (#7, #11)  (Charles River Laboratories)
90
Charles River Laboratories adenocarcinomas specimens from patients’ surgically resected tumors (srt) with egfr activating mutations (#7, #11)
Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . <t>SRT,</t> surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and <t>post</t> <t>EGFR-TKI</t> treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.
Adenocarcinomas Specimens From Patients’ Surgically Resected Tumors (Srt) With Egfr Activating Mutations (#7, #11), supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr-activating+mutations/adenocarcinomas+specimens+from+patients%E2%80%99+surgically+resected+tumors++srt++with+egfr+activating+mutations+++7+++11+/pmc10241979-90-42-61
Average 90 stars, based on 1 article reviews
adenocarcinomas specimens from patients’ surgically resected tumors (srt) with egfr activating mutations (#7, #11) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
osimertinib is an irreversible, central nervous system (cns) active egfr-tki, selective for both egfrm and t790m resistance mutations.  (AstraZeneca ltd)
90
AstraZeneca ltd osimertinib is an irreversible, central nervous system (cns) active egfr-tki, selective for both egfrm and t790m resistance mutations.
Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . <t>SRT,</t> surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and <t>post</t> <t>EGFR-TKI</t> treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.
Osimertinib Is An Irreversible, Central Nervous System (Cns) Active Egfr Tki, Selective For Both Egfrm And T790m Resistance Mutations., supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/egfr-activating+mutations/azd9291/10__1016_slash_j__jtho__2018__08__667-95-100-79
Average 90 stars, based on 1 article reviews
osimertinib is an irreversible, central nervous system (cns) active egfr-tki, selective for both egfrm and t790m resistance mutations. - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . SRT, surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and post EGFR-TKI treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.

Journal: iScience

Article Title: Stratification of non-small cell lung adenocarcinoma patients with EGFR actionable mutations based on drug-resistant stem cell genes

doi: 10.1016/j.isci.2023.106584

Figure Lengend Snippet: Validation of R-index in mice model and patients (A and B) R-index changes in mice between treatment-naive and osimertinib or Erlotinib treatment in-vivo . SRT, surgically resected tumors; PDX, patient-derived xenografts. (C) Changes of R-index and prognosis of patients pro- and post EGFR-TKI treatment. (D) Correlation plot of R-index and PFS. (E) Correlation of R-index and prognosis of patients’ pro- and post EGFR-TKI treatment and the median R-index is used to divide high and low drug resistance groups. (F) Correlation plot of R-index and PFS.

Article Snippet: Because the cells in culture lacked in-vivo interactions, we applied R-index to investigate the response of mice to EGFR-TKIs treatment from xenograft data., Patient-derived xenograft (PDX) models were built by implanting small pieces (3–5 mm) of adenocarcinomas specimens from patients’ surgically resected tumors (SRT) with EGFR activating mutations (#7, #11) into the subcutaneous flank tissue of female SHO mice (Crlj: SHO-PrkdcscidHrhr, Charles River).

Techniques: Biomarker Discovery, In Vivo, Derivative Assay